TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25592331
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen (800 mg) administered over 5 to 10 minutes preoperatively
Study: 25592632
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg orally once a day in 6-week cycles (4 weeks of treatment followed by 2 weeks without treatment)
Study: 25593079
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of CD133-positive enriched bone marrow progenitor cells
Study: 25594861
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) treatment for 0.8 years (median 0.5; 1.3)
Study: 25595221
Drug: OnabotulinumtoxinA treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA treatment, mean dose 189.8 ± 87.1U, average treatment intervals of 14.6 and 15.1 weeks.
Study: 25596263
Drug: Vorinostat 200
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 200 mg orally twice daily on days 1-14 and rituximab 375 mg/m² intravenously on day 1 of a 21-day cycle.
Study: 25599347
Drug: Treatment interruptions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interruptions or poor medication adherence
Study: 25603113
Drug: Oral washes
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral washes (OW)
Study: 25603823
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFNα and soluble Flt-1
Study: 25603823
Drug: Soluble Flt-1
Normalized name: 18F-FLT
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble Flt-1 treatment on human endothelial cells
Study: 25603822
Drug: Suboxone 2.0/0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboxone 2.0/0.5-mg tablet
Study: 25604779
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral nutritional supplements (ingestion of ⩾ 11/15 units)
Study: 25604779
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral nutritional supplements
Study: 25605368
Drug: Mogamulizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (1.0 mg/kg)
Study: 25605368
Drug: Mogamulizumab (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (0.1, 0.3, and 1.0 mg/kg)
Study: 25605552
Drug: Once-daily trientine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily trientine (15 mg/kg)
Study: 25605745
Drug: Romidepsin at
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles
Study: 25605745
Drug: Romidepsin treatment
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin treatment
Study: 25609248
Drug: OPB-51602 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-51602 at 5 mg intermittently
Study: 25609248
Drug: OPB-51602 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-51602 at 4 mg continuously
Study: 25609248
Drug: OPB-51602 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-51602 at 4 mg intermittently (Cohort B)
Study: 25609248
Drug: OPB-51602 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-51602 at 2 mg and 4 mg intermittently
Study: 25609248
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing of OPB-51602
Study: 25609248
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of OPB-51602
Study: 25609320
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (300 mg on day 1, 600 mg on day 2, adjusted to 400-800 mg thereafter)
Study: 25609333
Drug: C1-inhibitor (Berinert)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (Berinert) as on-demand therapy
Study: 25609333
Drug: C1-inhibitor (Berinert)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (Berinert) for prophylactic administration
Study: 25609333
Drug: C1-inhibitor (Berinert)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (Berinert) in home setting
Study: 25609333
Drug: C1-inhibitor (Berinert)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (Berinert) overall safety
Study: 25609333
Drug: C1-inhibitor (Berinert)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (Berinert) thromboembolic events
Study: 25609333
Drug: C1-inhibitor (Berinert)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (Berinert) safety profile
Study: 25612635
Drug: Oxaliplatin 60
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 60 mg/m(2)/week on days 1, 8, 22, and 29 plus S-1 80 mg/m(2)/day on days 1-5, 8-12, 22-27, and 29-33 with 50.4 Gy radiotherapy
Study: 25613597
Drug: Less education,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less education, younger age at injury, current or past treatment of depression, bipolar disorder or schizophrenia
Study: 25613716
Drug: dTpa booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa booster dose (0.5mg or 0.3mg formulations)
Study: 25613716
Drug: dTpa booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa booster dose (0.133mg group received 0.5mg formulation)
Study: 25613716
Drug: dTpa booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa booster dose
Study: 25614165
Drug: IW001 (col(V)
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IW001 (col(V) oral immunotherapeutic)
Study: 25614940
Drug: new agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: new agents under investigation
Study: 25614962
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) 60 mg plus Sofosbuvir (SOF) 400 mg once-daily for 12 weeks
Study: 25617154
Drug: Individualized yoga
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized yoga conducted three times weekly for three weeks.
Study: 25617726
Drug: Lubiprostone treatment
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone treatment for four weeks
Study: 25617726
Drug: Lubiprostone treatment
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone treatment
Study: 25620457
Drug: Cortrosyn(™) stimulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortrosyn(™) stimulated aldosterone level of 5 ng/dl (0·14 nmol/l)
Study: 25620668
Drug: Capsule colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule colonoscopy
Study: 25621498
Drug: Reduced decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced decitabine dosages (0.1-0.2 mg/kg/day)
Study: 25622640
Drug: NHS-IL2 (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHS-IL2 (0.15 mg/kg, 0.30 mg/kg, 0.45 mg/kg) plus radiotherapy (5x 4 Gy)
Study: 25622640
Drug: NHS-IL2 alone
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHS-IL2 alone (5 mg/kg; days 7-9) plus fractionated radiotherapy (3.6 Gy; days 0-4) plus cisplatin (4 mg/kg; day 0)
Study: 25622723
Drug: Immunophenotyping analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunophenotyping analysis using 12-color antibody panels.
Study: 25622919
Drug: Edrophonium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (10 mg) intravenous injection
Study: 25623151
Drug: Intranasal evaporative
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal evaporative cooling
Study: 25624177
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and radiation
Study: 25624326
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate (DMPA) with twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV)
Study: 25624327
Drug: Low-dose isavuconazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isavuconazole (400/200/200 mg loading doses on day 1 and 200/200 mg on day 2, followed by 200 mg once daily for days 3 to 28)
Study: 25624327
Drug: High-dose isavuconazole
Normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isavuconazole (doses doubled from low-dose regimen)
Study: 25624403
Drug: Arachidonic acid
Normalized name: Arachidonic acid
DrugBank: Arachidonic Acid (DB04557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arachidonic acid (ARA) 10 mg/kg per day for 15 days
Study: 25624403
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) 40 mg/kg single dose
Study: 25624403
Drug: Biochemical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemical and immunological profiles after ARA therapy
Study: 25627002
Drug: IMO-2055 (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-2055 (0.16 mg/kg)
Study: 25627002
Drug: IMO-2055 (0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-2055 (0.32 mg/kg)
Study: 25627002
Drug: IMO-2055 (0.48
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-2055 (0.48 mg/kg)
Study: 25629663
Drug: ChAd3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd3 vaccine (1×10(10) viral particles)
Study: 25629663
Drug: ChAd3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd3 vaccine (2.5×10(10) viral particles)
Study: 25629663
Drug: ChAd3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd3 vaccine (5×10(10) viral particles)
Study: 25629663
Drug: ChAd3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd3 vaccine followed by MVA booster
Study: 25629663
Drug: ChAd3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd3 vaccine
Study: 25631362
Drug: Home-based mindfulness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based mindfulness therapy
Study: 25632070
Drug: SB939 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB939 (60 mg/day every other day for 3 of 4 weeks)
Study: 25633714
Drug: Pradigastat 20
Normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat 20 mg single oral dose in patients with mild hepatic impairment
Study: 25633714
Drug: Pradigastat 20
Normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat 20 mg single oral dose in patients with moderate hepatic impairment
Study: 25633714
Drug: Pradigastat 20
Normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat 20 mg single oral dose in patients with severe hepatic impairment
Study: 25633882
Drug: Ranibizumab 0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5-mg
Study: 25633882
Drug: Ranibizumab 2.0-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 2.0-mg
Study: 25634486
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cystoscopy and nCLE
Study: 25635138
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg daily)
Study: 25637055
Drug: PAT-SM6 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAT-SM6 (0.3, 1, 3, and 6 mg/kg)
Study: 25637379
Drug: Fluorouracil, epirubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen with granulocyte colony-stimulating factor support followed by weekly paclitaxel
Study: 25637379
Drug: Dose-density regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-density regimen with FEC followed by weekly paclitaxel
Study: 25639506
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m² every 3 weeks with prednisolone 10 mg daily for up to 10 cycles
Study: 25642145
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg dose
Study: 25642392
Drug: Weekly multimodal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multimodal MRI follow-up including diffusion tensor imaging (DTI), perfusion imaging, FLAIR, and contrast-enhanced 3D T1-weighted MR.
Study: 25642774
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of insulin secretory kinetics
Study: 25644339
Drug: Bolus EAA
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus EAA feeding (15 g mixed-EAA as a single dose)
Study: 25644339
Drug: Spread EAA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spread EAA feeding (15 g mixed-EAA in 4 fractions at 45-min intervals)
Study: 25644958
Drug: Chimerism-based immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimerism-based immunotherapy (IT) with fast withdrawal of immunosuppression (FWI) and donor lymphocyte infusions (DLI)
Study: 25644958
Drug: Chimerism-based immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimerism-based immunotherapy (IT)
Study: 25645025
Drug: Influenza A/California/2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A/California/2009 (H1N1) virus, intranasally inoculated at increasing doses (up to 3.5 × 10(6) TCID50)
Study: 25645025
Drug: Influenza A/California/2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A/California/2009 (H1N1) virus, highest dose (3.5 × 10(6) TCID50)
Study: 25645660
Drug: IV voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV voriconazole (8.1±2.1 mg/kg/day)
Study: 25645660
Drug: SBECD (129±33
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBECD (129±33 mg/kg/day)
Study: 25645668
Drug: Uncertain treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertain treatment preferences
Study: 25645668
Drug: Doctor communication
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctor communication about treatment options
Study: 25645668
Drug: Life-sustaining treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-sustaining treatments for more than 7 days
Study: 25648230
Drug: Laparoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic surgery with intra-abdominal pressure of 9 mmHg (Group L)
Study: 25648341
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CyA) treatment
Study: 25648341
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CyA) treatment for approximately 6 months
Study: 25649171
Drug: Subvirion H3N2v
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion H3N2v vaccine (15 µg of hemagglutinin/dose), administered in 2 doses 21 days apart.
Study: 25651449
Drug: Rate-control drugs
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate-control drugs
Study: 25651449
Drug: Overall anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall anticoagulant therapy
Study: 25651830
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m²) + Dexamethasone (20 mg for 2 days with each Bz dose)
Study: 25652454
Drug: PF-05212384, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05212384, administered intravenously once weekly at a maximum-tolerated dose (MTD) of 154 mg
Study: 25653396
Drug: Abbott RealTime
Normalized name: LANCET,ABBOTT THIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbott RealTime HCV RNA assay (<12 IU/ml)
Study: 25653396
Drug: High Pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Pure System or Abbott RealTime (<12 IU/ml)
Study: 25653826
Drug: Quetiapine immediate-release
Normalized name: quetiapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine immediate-release (IR)
Study: 25654354
Drug: Rifampin 20
Normalized name: rifampin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 20 mg/kg (Experimental)
Study: 25654354
Drug: Rifampin 25
Normalized name: rifampin 25 mg/mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 25 mg/kg (Experimental)
Study: 25654354
Drug: Rifampin 30
Normalized name: rifampin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 30 mg/kg (Experimental)
Study: 25654354
Drug: Rifampin 35
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 35 mg/kg (Experimental)
Study: 25654812
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) 60-mg single dose
Study: 25655379
Drug: Siltuximab 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 5.5 mg/kg
Study: 25655379
Drug: Siltuximab 11.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 11.0 mg/kg
Study: 25655379
Drug: Siltuximab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab (both doses)
Study: 25656734
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV7)
Study: 25659285
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg once daily) plus Ribavirin (1000 mg or 1200 mg twice daily for 24 weeks or 12 weeks for treatment-naive genotype-2 patients)
Study: 25660004
Drug: Transition preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition preparation program
Study: 25664185
Drug: Atazanavir/Ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/Ritonavir 300/100 mg qd
Study: 25664185
Drug: Atazanavir/Ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/Ritonavir 400/100 mg qd
Study: 25664404
Drug: Self-injection with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-injection with the autoinjector (50 mg subcutaneous golimumab once monthly for 6 months)
Study: 25664404
Drug: Self-injection with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-injection with the autoinjector
Study: 25664534
Drug: Dual mapping
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual mapping agents (radiolabeled colloid and blue dye)
Study: 25664604
Drug: Oral octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral octreotide capsules (OOCs) 40 mg/d, escalated to 60 mg/d and then 80 mg/d for 7 months
Study: 25665464
Drug: SB-743921 with
Normalized name: SB-743921
DrugBank: SB-743921 (DB05546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-743921 with G-CSF (9 mg/m² MTD)
Study: 25665464
Drug: SB-743921 without
Normalized name: SB-743921
DrugBank: SB-743921 (DB05546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-743921 without G-CSF (6 mg/m² MTD)
Study: 25667206
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 1000 mg, two doses
Study: 25667274
Drug: Standard-of-care therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care therapies or biomarker-matched treatment groups
Study: 25667281
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy without IGRT (from CAN-NCIC-SR2 trial)
Study: 25668820
Drug: Stable antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable antiretroviral therapy
Study: 25669310
Drug: Dietary cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cysteine intake (mean, 635 mg/d)
Study: 25669662
Drug: Pilaralisib 400
Normalized name: Pilaralisib
DrugBank: Pilaralisib (DB11772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilaralisib 400 mg plus erlotinib 150 mg
Study: 25670018
Drug: [(99m)Tc]Tilmanocept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(99m)Tc]Tilmanocept (50 µg, radiolabeled with either 0.5 mCi same day or 2.0 mCi next day)
Study: 25672894
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide for 1 year
Study: 25672916
Drug: Buparlisib (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 175 mg/m(2) on day 1 of a 21-day cycle with pegfilgrastim support (Group 1)
Study: 25672916
Drug: Buparlisib (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 80 mg/m(2) on days 1, 8, and 15 of a 28-day cycle without growth factor support (Group 2)
Study: 25677668
Drug: Ziv-aflibercept (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept (1.25 mg, 0.05 mL intravitreal injection)